coadministered cagrilintide and semaglutide in adults with overweight or obesity Summary of REDEFINE 1 REDEFINE 2 trials CagriSema, presented this week at #ADA2025 and published NEJM: REDEFINE 1: • 👥 3,417 participants with (without diabetes) treated In the REDEFINE 2 phase

Across all agents and doses, placebo-adjusted mean weight loss was 10.9 per cent, accompanied by a systolic blood pressure reduction of 5.2 millimetres of mercury

Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the us FDA adverse event reporting system database

For Ozempic pens, the volume delivered varies by pen strength: For the 2 mg/1.5 mL pen (1.34 mg/mL): 0.25 mg dose = 0.19 mL 0.5 mg dose = 0.37 mL For the 4 mg/3 mL pen (1.34 mg/mL): For the 8 mg/3 mL pen (2.67 mg/mL): For Wegovy single-dose pens, each pen is designed to deliver its entire contents as one dose

[1] [2] Anesthesiologists may employ risk mitigation strategies including rapid sequence induction, cricoid pressure, use of medications to reduce gastric acidity (proton pump inhibitors, H2-blockers), and consideration of point-of-care gastric ultrasound to assess residual gastric volume

GLP-1 agonists alone cannot treat Type 2 diabetes or obesity, but both conditions require other treatment strategies, like lifestyle and dietary changes

Some, like Cheryl Boveenow legally blind after taking Ozempicare demanding accountability for the harm suffered